Improvements in muscle recovery and delayed onset muscle soreness (DOMS) reduction after eccentric exercise with the BounceBack™ product: a randomised, double-blind, two-way crossover, placebo-controlled, pilot study

INTERVENTION: The test product is BounceBack™, which contains enzymes, curcumin, vitamin C, avocado, soy extract and resveratrol. Dosage: BounceBack™ (oral) 1000 mg/day Schedule of interventions: Thirty days of consumption of the test product or placebo, followed by exercise on Day 31 and post‐exercise evaluations on Day 32, 33 and 34. After a two‐week washout period, the intervention was repeated in a crossover design. CONDITION: Delayed onset muscle soreness (DOMS) ; Musculoskeletal Diseases PRIMARY OUTCOME: Pain (Visual Analogue Scale [VAS]) and tenderness, assessed at baseline (pre‐exercise), and then at 6, 24, 48 and 72 hours post‐exercise. SECONDARY OUTCOME: The following were assessed at baseline (pre‐exercise), and then at 6, 24, 48 and 72 hours post‐exercise:; 1. Inflammation; 2. Muscle damage INCLUSION CRITERIA: 1. Both males and females, age >=18 and <=45 at screening 2. Body mass index (BMI) >18 kg/m^2 and <=30 kg/m^2 at screening 3. Recreationally active but non‐resistance trained for the preceding 3 months 4. Agree to dietary modifications for the day prior to each visit 5. Subject agrees to all study visits 6. Must agree to use appropriate birth control methods during the active study